Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U3 Pharma AG

Division of Daiichi Sankyo Co. Ltd.
www.u3pharma.com

Latest From U3 Pharma AG

Daiichi Closing Indian Site As Global Restructuring Continues

Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.

Commercial Companies

Daiichi Sankyo Loses One, Gains One In Oncology

Daiichi Sankyo has unveiled disappointing results for one pipeline molecule that has now been suspended for lung cancer, but has gained another for breast cancer as it continues to develop its oncology portfolio.

BioPharmaceutical Asia Pacific

Daiichi Sankyo Hoping Its Post-Olmesartan Plan Comes Together

"I love it when a plan comes together," Hannibal Smith of TV show The A-Team used to say, a catchphrase which Daiichi Sankyo will be hoping is appropriate in around five years' time as it looks back on the results of its new mid-term strategy.

BioPharmaceutical Japan

Merck Brings Firepower To Daiichi’s EU Lixiana Campaign

Following the European approval of Lixiana last year, Daiichi Sankyo has tapped Merck & Co to maximize regional sales of the novel anticoagulant in markets where it has limited reach, but will face multiple competitors.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Daiichi Sankyo Co. Ltd.
  • Senior Management
  • Irina Staatz-Granzer, PhD, CEO
    Mike Rothe, PhD, CSO
  • Contact Info
  • U3 Pharma AG
    Phone: (49) 89 8103 90
    Bunsenstrasse 1
    Martinsried, 82152
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register